A Drug Company Exploited a Safety Requirement to Make Money

February 28, 2023

(New York Times) – Jazz’s narcolepsy drug, which is used by thousands of patients, is enormously lucrative, generating more than $13 billion in revenue since Jazz acquired it in 2005. Medicare now spends hundreds of millions of dollars annually for it. The drug accounted for 58 percent of Jazz’s revenue in 2021. In other words, for every month that Jazz could delay the arrival of competition, the company and its shareholders stood to benefit financially. But the tactics deprived narcolepsy patients of access to a new drug that was much easier to take. (Read More)